Literature DB >> 34124702

SARS-CoV-2 emerging variants in Africa: view from Gabon.

Samira Zoa-Assoumou1,2, Bénédicte Ndeboko3,4, Gédéon Prince Manouana5,6, Rotimi Myrabelle Avome Houechenou4, Rodrigue Bikangui6, Amandine Mveang-Nzoghe4, Georgelin Nguema Ondo6, Elvyre Mbongo-Kama2, Bertrand Lell6,7, Haruka Abe8, Yuri Ushijima8, Anne-Marie Antchouey9, Jiro Yasuda8, Ayola Akim Adegnika5,6,10, Joel Fleury Djoba Siawaya4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34124702      PMCID: PMC8186850          DOI: 10.1016/S2666-5247(21)00125-7

Source DB:  PubMed          Journal:  Lancet Microbe        ISSN: 2666-5247


× No keyword cloud information.
Since SARS-CoV-2 appeared in late 2019 in Wuhan, China, variants have emerged around the world. The general concern is that these variants appear to cause more severe disease, spread more easily between humans, and might change the effectiveness of current treatment and vaccines.1, 2, 3, 4, 5 Travel-related dissemination of SARS-CoV-2 fuels the global pandemic and the spread of variants. Therefore, SARS-CoV-2 genomic surveillance would help trace the emergence and spread of variants to better understand and anticipate their impact on public health. SARS-CoV-2 genomic surveillance in Africa has been portrayed as a challenge. Nevertheless, Gabon has taken up the challenge of setting up and implementing SARS-CoV-2 genomic surveillance. Gabon's strategy in the fight against COVID-19 includes SARS-CoV-2 PCR testing of volunteers and travellers (this applies to travel into and out of Gabon, as well as interprovincial travel within Gabon); contact tracing; and treatment. Here, we report the first data of the Gabonese genomic surveillance initiative. A total of 120 samples from individuals diagnosed by PCR with SARS-CoV-2 infection between Jan 31, 2021, and March 4, 2021, were selected. 100 (83·3%) samples were from international travellers and 20 (16·7%) were from family clusters. A total of 106 samples were successfully sequenced (by use of the Sanger method). Variants were found in 86 (81·1%) of 106 samples. The British variant (B.1.1.7) was found in 43 (40%) of 106 samples, variant B.1.525 was found in 34 (32%) of 86 samples, six (6%) of 106 samples had the South African variant (B.1.351), and three (3%) of 106 samples had the Indian variant. To the best of our knowledge, this is the first report of the presence of the SARS-CoV-2 Indian variant in Africa. Origins-based analysis (appendix) showed that the British variant of the B.1.1.7 lineage was found mainly in passengers from Burkina Faso (14), in family clusters (11), and in passengers from France (six). The B1.525 variant was found mainly in passengers from Cameroon (13), followed by Nigeria (eight). The South African variant (B.1.351) was detected in passengers who came from Cameroon (two), France (two), Guinea (one), and Côte d'Ivoire (one). Our data clearly show that SARS-CoV-2 variants are spreading throughout Africa. The B.1.525 variant was isolated from a patient arriving from Nigeria. This variant first emerged in Nigeria and the UK. The B.1.351 variant (South African variant) was supposedly introduced by two patients who arrived in Gabon from France. The detection of the B.1.1.7 variant in community samples after its first detection in December, 2020 (GenBank: MW650650.1) highlights the spread of this variant in Gabon. Our findings highlight the introduction and circulation in Gabon of SARS-CoV-2 variants including British, South African, and Indian variants. Beyond Gabon, our data reveal the circulation of SARS-CoV-2 variants in many sub-Saharan African countries. These distributions should be interpreted with due consideration of surveillance limitations, including differences in sequencing capacities and prioritisation of samples for sequencing between countries. In conclusion, variants with concerning mutations were found from our surveillance. Currently, additional sequencing is ongoing to better understand the origin, prevalence, and transmission characteristics of these SARS-CoV-2 variants. We declare no competing interests. Financial support was provided by the Gabonese Government. The study was authorised by the national Comité de pilotage du Plan de veille et de Riposte sur L'épidémie à Coronavirus (COPIL-CORONAVIRUS). We gratefully acknowledge Guy-Patrick Obiang Ndong, Gabonese Ministry of Health, for his contribution to this project. We also acknowledge the Gabonese COVID-19 Scientific Committee. We thank the staff of Laboratoire Professeur Daniel Gahouma, CHU Mère-Enfant Fondation Jeanne Ebori, and CERMEL for their commitment to the fight against COVID -19.
  4 in total

1.  Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01.

Authors:  David Harrington; Beatrix Kele; Spiro Pereira; Xose Couto-Parada; Anna Riddell; Suzanne Forbes; Hamish Dobbie; Teresa Cutino-Moguel
Journal:  Clin Infect Dis       Date:  2021-11-16       Impact factor: 9.079

2.  Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant.

Authors:  Marielle Bedotto; Pierre-Edouard Fournier; Linda Houhamdi; Anthony Levasseur; Jeremy Delerce; Lucile Pinault; Abdou Padane; Amanda Chamieh; Hervé Tissot-Dupont; Philippe Brouqui; Cheikh Sokhna; Eid Azar; Rachid Saile; Souleymane Mboup; Idir Bitam; Philippe Colson; Didier Raoult
Journal:  J Clin Virol       Date:  2021-03-31       Impact factor: 3.168

Review 3.  Reinfection With SARS-CoV-2: Implications for Vaccines.

Authors:  Jeffrey I Cohen; Peter D Burbelo
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

4.  Evidence of SARS-CoV-2 re-infection with a different genotype.

Authors:  Philippe Colson; Michael Finaud; Nicolas Levy; Jean-Christophe Lagier; Didier Raoult
Journal:  J Infect       Date:  2020-11-15       Impact factor: 6.072

  4 in total
  5 in total

1.  Delays in the arrival of the waves of COVID-19: a comparison between Gabon and the African continent.

Authors:  Haruka Abe; Yuri Ushijima; Rodrigue Bikangui; Georgelin Nguema Ondo; Bertrand Lell; Ayola A Adegnika; Jiro Yasuda
Journal:  Lancet Microbe       Date:  2022-04-21

2.  Screening and Whole Genome Sequencing of SARS-CoV-2 Circulating During the First Three Waves of the COVID-19 Pandemic in Libreville and the Haut-Ogooué Province in Gabon.

Authors:  Sonia Etenna Lekana-Douki; Nadine N'dilimabaka; Anthony Levasseur; Philippe Colson; Julia Cyrielle Andeko; Ornella Zong Minko; Octavie Banga Mve-Ella; Pierre-Edouard Fournier; Christian Devaux; Bertrand Mve Ondo; Falone Larissa Akombi; Laurianne Yacka Mouele Bolo; Audrey Michel Ngonga Dikongo; Abdoulaye Diané; Arsène Mabika Mabika; Jenny Francine Mathouet; Cresh Dzembo; Nick Chenis Atiga; Anicet Mouity Matoumba; Nal Kennedy Ndjangangoye; Ludivine Bréchard; Marielle Bedotto-Buffet; Joa Braithe Mangombi Pambou; Marisca Kandet Yattara; Elvire Anita Mbongo Nkama; Armel Mintsa Ndong; Ayola Akim Adegnika; Didier Raoult; Florence Fenollar; Jean-Bernard Lekana-Douki
Journal:  Front Med (Lausanne)       Date:  2022-05-17

3.  The COVID-19 pandemic in the African continent.

Authors:  Godfrey Bwire; Alex Riolexus Ario; Patricia Eyu; Felix Ocom; Joseph F Wamala; Kwadwo A Kusi; Latif Ndeketa; Kondwani C Jambo; Rhoda K Wanyenze; Ambrose O Talisuna
Journal:  BMC Med       Date:  2022-05-02       Impact factor: 11.150

4.  Emergence of B.1.1.318 SARS-CoV-2 viral lineage and high incidence of alpha B.1.1.7 variant of concern in the Republic of Gabon.

Authors:  Gédéon Prince Manouana; Moustapha Nzamba Maloum; Rodrigue Bikangui; Sam O'neilla Oye Bingono; Georgelin Ondo Nguema; Josiane Yabo Honkpehedji; Elie Gide Rossatanga; Samira Zoa-Assoumou; Srinivas Reddy Pallerla; Sivaramakrishna Rachakonda; Armel Ndong Mintsa; Jean-Bernard Lekana-Douki; Joël-Fleury Djoba Siawaya; Steffen Borrmann; Peter Gottfried Kremsner; Bertrand Lell; Thirumalaisamy P Velavan; Ayola Akim Adegnika
Journal:  Int J Infect Dis       Date:  2021-11-03       Impact factor: 12.074

5.  Psychological stress self-help interventions for healthcare workers in the context of COVID-19 in China: A randomized controlled trial protocol.

Authors:  Rui Luo; Pengyue Guo; Menglin Shang; Yuqi Cai; Jinying Huang; Yiling He; Phoenix K H Mo; Anise M S Wu; Roman Dong Xu; Jinghua Li; Joseph T F Lau; Jing Gu
Journal:  Internet Interv       Date:  2022-04-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.